摘要
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents a global health emergency that is in urgent need of intervention(1-3). The entry of SARS-CoV-2 into its target cells depends on binding between the receptor-binding domain (RBD) of the viral spike protein and its cellular receptor, angiotensin-converting enzyme 2 (ACE2)(2,4-6). Here we report the isolation and characterization of 206 RBD-specific monoclonal antibodies derived from single B cells from 8 individuals infected with SARS-CoV-2. We identified antibodies that potently neutralize SARS-CoV-2; this activity correlates with competition with ACE2 for binding to RBD. Unexpectedly, the anti-SARS-CoV-2 antibodies and the infected plasma did not cross-react with the RBDs of SARS-CoV or Middle East respiratory syndrome-related coronavirus (MERS-CoV), although there was substantial plasma cross-reactivity to their trimeric spike proteins. Analysis of the crystal structure of RBD-bound antibody revealed that steric hindrance inhibits viral engagement with ACE2, thereby blocking viral entry. These findings suggest that anti-RBD antibodies are largely viral-species-specific inhibitors. The antibodies identified here may be candidates for development of clinical interventions against SARS-CoV-2. @@@ In a study of antibodies isolated from patients infected with SARS-CoV-2, antibodies that potently neutralized the virus competed with angiotensin-converting enzyme 2 for binding to the receptor-binding domain of the viral spike protein, suggesting that antibodies that disrupt this interaction could be developed to treat SARS-CoV-2 infection.
学科与关键词
- Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicryGe, Jiwan; Wang, Ruoke; Ju, Bin; Zhang, Qi; Sun, Jing; Chen, Peng; Zhang, Senyan; Tian, Yuling; Shan, Sisi; Cheng, Lin; Zhou, Bing; Song, Shuo; Zhao, Juanjuan; Wang, Haiyan; Shi, Xuanling; Ding, Qiang; Liu, Lei; Zhao, Jincun; Zhang, Zheng*; Wang, Xinquan*; Zhang, Linqi*Nature Communications, 2021, 12(1): 250.被引 79
- Perspectives on the development of neutralizing antibodies against SARS-CoV-2Mitchell, HoAntibody Therapeutics, 2020, 3(2): 109-114.被引 7
- A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike proteinLi, Yan; Wan, Yuhua; Liu, Peipei; Zhao, Jincun; Lu, Guangwen; Qi, Jianxun; Wang, Qihui; Lu, Xuancheng; Wu, Ying; Liu, Wenjun; Zhang, Buchang; Yuen, Kwok-Yung; Perlman, Stanley; Gao, George F.; Yan, Jinghua*Cell Research, 2015, 25(11): 1237-1249.被引 112
